Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
Previous Symbol
CUSIPN/A
Phone617-467-4577
Debt
Debt-to-Equity Ratio0.17
Current Ratio14.75
Quick Ratio14.75
Price-To-Earnings
Trailing P/E Ratio-1.93
Forward P/E Ratio-5.17
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.01 per share
Price / Book2.31
Profitability
EPS (Most Recent Fiscal Year)($4.80)
Net Income$-21,650,000.00
Net MarginsN/A
Return on Equity-46.07%
Return on Assets-38.80%
Miscellaneous
Employees34
Outstanding Shares20,760,000
Market Cap$192.25 million
OptionableNot Optionable
Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions
What is Allena Pharmaceuticals' stock symbol?
Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How were Allena Pharmaceuticals' earnings last quarter?
Allena Pharmaceuticals Inc (NASDAQ:ALNA) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.01. View Allena Pharmaceuticals' Earnings History.
When is Allena Pharmaceuticals' next earnings date?
What price target have analysts set for ALNA?
7 brokerages have issued 12-month target prices for Allena Pharmaceuticals' stock. Their predictions range from $21.00 to $61.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $31.6667 in the next twelve months. This suggests a possible upside of 242.0% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.
What is the consensus analysts' recommendation for Allena Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.
What are Wall Street analysts saying about Allena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (11/12/2018)
- 2. Cowen Inc analysts commented, "We expect SEL-212 to show (1) superior efficacy, (2) better safety, and (3) less frequent dosing vs Krystexxa in the head-to-head study, giving SEL-212 a major commercial advantage." (8/8/2018)
- 3. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)
Has Allena Pharmaceuticals been receiving favorable news coverage?
Media coverage about ALNA stock has trended very positive on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a coverage optimism score of 3.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the immediate future.
Who are some of Allena Pharmaceuticals' key competitors?
Some companies that are related to Allena Pharmaceuticals include Twist Bioscience (TWST), Heska (HSKA), Vericel (VCEL), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), Scholar Rock (SRRK), Avrobio (AVRO), Adaptimmune Therapeutics (ADAP), NanoString Technologies (NSTG), Replimune Group (REPL), PDL BioPharma (PDLI), Mesoblast (MESO), Translate Bio (TBIO), Nightstar Therapeutics (NITE) and CASI Pharmaceuticals (CASI).
Who are Allena Pharmaceuticals' key executives?
Allena Pharmaceuticals' management team includes the folowing people:
- Dr. Alexey L. Margolin, Co-Founder, CEO & Director (Age 65)
- Dr. Louis Brenner, Pres & COO (Age 48)
- Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 58)
- Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 53)
- Mr. Hugh Wight, VP of Technical Operations
When did Allena Pharmaceuticals IPO?
(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Allena Pharmaceuticals' major shareholders?
Allena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Morgan Stanley (8.94%), Partner Fund Management L.P. (8.52%), FMR LLC (7.18%), BlackRock Inc. (2.78%), Vanguard Group Inc. (1.69%) and Sphera Funds Management LTD. (1.42%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.
Which institutional investors are selling Allena Pharmaceuticals stock?
Which institutional investors are buying Allena Pharmaceuticals stock?
ALNA stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Partner Fund Management L.P., Sphera Funds Management LTD., Citadel Advisors LLC, BlackRock Inc., Vanguard Group Inc. and Alps Advisors Inc.. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.
How do I buy shares of Allena Pharmaceuticals?
Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allena Pharmaceuticals' stock price today?
One share of ALNA stock can currently be purchased for approximately $9.26.
How big of a company is Allena Pharmaceuticals?
Allena Pharmaceuticals has a market capitalization of $192.25 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.
What is Allena Pharmaceuticals' official website?
How can I contact Allena Pharmaceuticals?
Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.
MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
